• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Practical management and assessment of primary plasma cell leukemia in the novel agent era.

作者信息

Visram A, Suska A, Jurczyszyn A, Gonsalves W I

机构信息

University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Division of Hematology, Mayo Clinic, Rochester, MN, United States.

Department of Hematology, Jagiellonian University Medical College, Kopernika 17, Krakow 31-501, Poland.

出版信息

Cancer Treat Res Commun. 2021;28:100414. doi: 10.1016/j.ctarc.2021.100414. Epub 2021 Jun 8.

DOI:10.1016/j.ctarc.2021.100414
PMID:34174530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8405542/
Abstract
摘要

相似文献

1
Practical management and assessment of primary plasma cell leukemia in the novel agent era.新型药物时代原发性浆细胞白血病的实践管理与评估
Cancer Treat Res Commun. 2021;28:100414. doi: 10.1016/j.ctarc.2021.100414. Epub 2021 Jun 8.
2
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.原发性浆细胞白血病：新型诱导药物时代的自体造血干细胞移植。
Bone Marrow Transplant. 2019 Jul;54(7):1089-1093. doi: 10.1038/s41409-018-0392-1. Epub 2018 Nov 16.
3
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.新型药物治疗时代原发性浆细胞白血病患者的临床特征与结局
Mayo Clin Proc. 2021 Mar;96(3):677-687. doi: 10.1016/j.mayocp.2020.06.060.
4
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience.原发性浆细胞白血病的细胞遗传学与治疗特征：IFM研究经验
Leukemia. 2012 Jan;26(1):158-9. doi: 10.1038/leu.2011.176. Epub 2011 Jul 29.
5
First reported case of leukocytapheresis in plasma cell leukemia.浆细胞白血病中白细胞单采术的首例报道病例。
Transfusion. 2020 Jan;60(1):11-12. doi: 10.1111/trf.15564. Epub 2019 Nov 4.
6
Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows.治疗原发性浆细胞白血病的新型药物：光明与阴影
Acta Haematol. 2016;135(2):110-2. doi: 10.1159/000441345. Epub 2015 Oct 28.
7
First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018.荷兰新诊断原发性浆细胞白血病患者的一线治疗与生存情况：一项基于人群的研究，1989 - 2018年
Blood Cancer J. 2021 Feb 4;11(2):22. doi: 10.1038/s41408-021-00415-5.
8
[Plasma cell leukemia in a 65 year old patient].[一名65岁患者的浆细胞白血病]
Wiad Lek. 1990 Jul 15;43(14):742-5.
9
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.新型药物时代下原发性浆细胞白血病预后和结局的真实世界数据：希腊骨髓瘤研究组的一项多中心全国性研究。
Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.
10
Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia.美法仑/全身照射预处理的清髓性异基因造血细胞移植治疗原发性浆细胞白血病患者
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e225-8. doi: 10.1016/j.clml.2014.07.012. Epub 2014 Aug 2.

引用本文的文献

1
Primary Plasma Cell Leukemia: Recent Advances in Molecular Understanding and Treatment Approaches.原发性浆细胞白血病：分子认识与治疗方法的最新进展
Int J Mol Sci. 2025 Jun 26;26(13):6166. doi: 10.3390/ijms26136166.
2
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.改变方向：将嵌合抗原受体T细胞疗法扩展至高危浆细胞异常增殖性疾病
Front Immunol. 2025 Apr 8;16:1558275. doi: 10.3389/fimmu.2025.1558275. eCollection 2025.
3
Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.蛋白酶体抑制剂和免疫调节剂时代原发性浆细胞白血病患者的生存结局：一项真实世界多中心分析
Turk J Haematol. 2024 Dec 2;41(4):225-235. doi: 10.4274/tjh.galenos.2024.2023.0450. Epub 2024 Nov 6.
4
Evolving progress in the management of malignant plasma cell disorders.恶性浆细胞疾病管理方面的进展演变
Cancer Treat Res Commun. 2022;32:100612. doi: 10.1016/j.ctarc.2022.100612. Epub 2022 Jul 19.

本文引用的文献

1
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.新型药物治疗时代原发性浆细胞白血病患者的临床特征与结局
Mayo Clin Proc. 2021 Mar;96(3):677-687. doi: 10.1016/j.mayocp.2020.06.060.
2
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.硼替佐米、来那度胺和地塞米松联合或不联合依洛珠单抗治疗未经治疗的高危多发性骨髓瘤患者（SWOG-1211）：一项随机、2 期试验的主要分析。
Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22.
3
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
4
Covid-19: Herd immunity is "unethical and unachievable," say experts after report of 5% seroprevalence in Spain.新冠疫情：西班牙报告血清阳性率为5%后，专家称群体免疫“不道德且无法实现”。
BMJ. 2020 Jul 7;370:m2728. doi: 10.1136/bmj.m2728.
5
Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.原发性浆细胞白血病：来自中国单中心研究的 46 例真实世界回顾性研究。
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e652-e659. doi: 10.1016/j.clml.2020.05.014. Epub 2020 May 27.
6
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).SWOG S0777 随机 III 期试验的长期随访：硼替佐米、来那度胺和地塞米松与来那度胺和地塞米松治疗未经治疗的多发性骨髓瘤且无立即进行自体干细胞移植（ASCT）意向的患者。
Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8.
7
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
8
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤：GRIFFIN 试验。
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
9
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.原发性浆细胞白血病在当前时代的造血细胞移植利用和结果。
Leukemia. 2020 Dec;34(12):3338-3347. doi: 10.1038/s41375-020-0830-0. Epub 2020 Apr 20.
10
Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia.利用多参数流式细胞术诊断原发性浆细胞白血病患者。
Am J Hematol. 2020 Jun;95(6):637-642. doi: 10.1002/ajh.25773. Epub 2020 Mar 26.